#### **Overview** Anuh Pharma Ltd. (APL) is a mid-sized Indian manufacturer of Active Pharmaceutical Ingredients (APIs), specializing in macrolide antibiotics, anti-TB, anti-malarial, anti-diabetic, corticosteroid, and dermatological APIs. Established in 1960 and part of the ₹8.5 billion SK Group, APL has evolved into one of the world’s leading producers of **first-generation Erythromycin salts** and **Pyrazinamide**, with growing prominence in diabetes, cardiovascular, and central nervous system (CNS) therapeutics. The company operates a **WHO-GMP and EU-GMP pre-qualified manufacturing facility** in Boisar (Tarapur), Maharashtra, and maintains a dedicated R&D center in Mahape, Navi Mumbai. With commercial operations in over **85 countries**, it serves more than **1,200 global customers**, including major multinational generics, formulators, and procurement agencies. --- #### **Financial & Operational Highlights (as of FY2025)** - **Revenue**: ₹661 crore in FY2025, following marginal YoY decline in H1 FY25 due to volume timing and lower realizations in high-margin markets. - **Export Contribution**: ~47% of total sales, primarily to Europe, Africa, Mexico, and emerging markets, making earnings sensitive to **INR–USD exchange rate fluctuations** (partially mitigated through natural hedging). - **Growth Outlook**: Targeting **15–20% revenue growth in FY2026**, supported by new product launches, geographic expansion, and enhanced manufacturing efficiency. - **Net Debt Position**: Zero net debt, reflecting strong financial health and favorable supplier credit terms. - **Manufacturing Capacity**: - Total API capacity expanded to **2,400 MTPA** across **9 API blocks and 2 intermediate blocks**. - Commissioned state-of-the-art facility at Tarapur (11,400 sq. m) with **Zero Liquid Discharge (ZLD)** compliant operations. - Dedicated **L&L site** for corticosteroids with **12 MTPA** capacity. - **Capital Investment**: Ongoing investments to expand capacity, reduce solvent usage, enhance yield, and support backward integration. --- #### **Regulatory and Quality Strengths** Anuh Pharma has an impressive regulatory footprint with approvals from: - **WHO Prequalification (PQ)**: Pyrazinamide, Sulphadoxine, Pyrimethamine. - **EDQM (CEP)**: Erythromycin Base, Erythromycin Ethyl Succinate, Pyrazinamide, Ambroxol HCl, Gliclazide, Azithromycin (in process), and others (total **8 CEPs**). - **USFDA**: Approval and DMF for Ambroxol HCl; active pursuit for newer products. - **EU-GMP / COS**: For Erythromycin, Erythromycin derivatives, and Pyrazinamide. - **COFEPRIS (Mexico)**: For Erythromycin and Chloramphenicol derivatives. - **UK MHRA DMF**: For Erythromycin Stearate. Facility-level approvals from multiple **multinational pharmaceutical companies** further validate its quality and compliance standards. --- #### **Strategic Focus Areas** 1. **Market Leadership & Diversification** - Holds **market leadership** in Erythromycin salts, Pyrazinamide, Sulfadoxine, Ambroxol HCl, Gliclazide, Clobetasol Propionate, and Betamethasone Dipropionate. - Dominant in **commoditized APIs** but actively transitioning toward **high-value, complex molecules** to counter price competition. - Expanding presence in **dermatology**, **CNS disorders**, **hypertension**, and **lifestyle diseases**. 2. **Geographic Expansion** - Prioritizing entry into **underpenetrated markets** such as Vietnam, Japan, South Korea, Brazil, and North America. - Strengthening relationships in **donor-funded African programs** via European procurement channels. - Aiming for a balanced domestic-export revenue mix over time. 3. **R&D and New Product Development** - **R&D Strategy**: Focus on **complex chemistry APIs** in diabetes, cardiovascular, anti-infectives, and CNS. - **Pipeline (2025–2027)**: - Anti-diabetics: **Linagliptin, Dapagliflozin, Empagliflozin, Vildagliptin, Gliclazide**. - Anti-platelets: **Ticagrelor**. - Anti-ulceratives: **Vonoprazan (Vonoprazon) Fumarate**. - Anti-TB: **Pretomanid, Bedaquiline Fumarate, Ethambutol**. - Anti-malarials: **Pyronaridine Tetraphosphate, Amodiaquine HCl**. - Neuroprotective agents: **Citicoline Sodium**. - Others: **Sulfadimethoxine, Acebrophylline, Allopurinol**. - Actively preparing **validation and commercial batches** for 11 new products using the **December 2019-commissioned plant**. - Plans to launch **5–6 new products annually**. 4. **Regulatory and Compliance Advantage** - Pursuing **CEP**, **USFDA**, and **WHO PQ** approvals for new pipeline products. - Leverages **ZLD system** to comply with global EHS norms and strengthen environmental sustainability profile. 5. **Backward Integration & Cost Optimization** - Strategic goal to **reduce dependency on Chinese intermediates** through backward integration in key APIs. - Focus on improving **process efficiency, yield, and solvent recovery** to reduce pollution and production costs. - Implementing **briquette-fired boilers and economizers** to lower fuel and power expenses. 6. **Inorganic Growth Strategy** - Evaluating **mergers and acquisitions** to accelerate market access and achieve synergies. - Exploring development of a **second manufacturing unit** to reduce facility concentration risk. --- #### **Competitive Advantages** - **Regulatory Approvals**: Robust approvals enabling access to high-margin regulated markets (US, EU, UK, Mexico). - **Scale and Capacity**: Among the **top 5 global producers** of Erythromycin salts; **world’s largest producer of Pyrazinamide**. - **Export Network**: Products exported to **85+ countries**, including access to **Global Fund and WHO procurement agencies**. - **Environmental Compliance**: **ZLD system** enhances regulatory credibility and sustainability. - **Financial Strength**: No net debt, strong client credit ratings, and high capital efficiency due to low-cost facility construction. - **Operational Stability**: Lower-than-industry employee attrition ensures process consistency and continuity. --- #### **Leadership & Governance** - **Mr. Pradeep Thakur** (Postgraduate in Chemistry, Jamnalal Bajaj Institute training) brings over **30 years** of experience from Cipla, Dr. Reddy’s, and Aceto Pharma. Currently leads strategic direction as key executive. - **Mr. Gaurav Shah** oversees API and logistics businesses within the SK Group, driving commercial and operational synergy.